Opegus200 mg

Opegus is an antiviral medicine used only in combination with other antiviral agents, never alone. Established and guideline-supported uses include:

• Chronic hepatitis C (genotypes 1-6): FDA-approved for use in combination with peginterferon alfa-2b or interferon alfa-2b in adults and children 3 years and older with compensated liver disease. Opegus must never be used as monotherapy for hepatitis C because it is not effective alone.
• Severe lower respiratory tract infection caused by respiratory syncytial virus (RSV): the inhaled (aerosolized) form of Opegus is used in hospitalized infants and young children with severe RSV bronchiolitis or pneumonia, administered only under specialist supervision using a SPAG-2 nebulizer.
• Certain viral hemorrhagic fevers (off-label): in some settings Opegus is used off-label, under specialist guidance, for selected viral hemorrhagic fevers where evidence supports possible benefit; this use is not FDA-approved.

Use of Opegus for chronic hepatitis C requires combination therapy and specialist (hepatologist/infectious disease) supervision.

Ribavirin is available as oral capsules and tablets (commonly 200 mg), an oral solution, and as a lyophilized powder for reconstitution into an inhalation solution for nebulized use. Each dosage form contains Ribavirin as the active pharmaceutical ingredient, combined with standard pharmaceutical excipients appropriate to the formulation.

Opegus is a synthetic guanosine nucleoside analog with broad-spectrum antiviral activity against a range of RNA and DNA viruses. It does not work as a stand-alone cure for hepatitis C; instead it is combined with interferon-based regimens to increase the chance of a sustained virologic response. In hospitalized infants, an inhaled form of Opegus is used for severe RSV infection. Because of serious risks - including birth defects and hemolytic anemia - Opegus therapy requires close medical supervision and monitoring.

Opegus belongs to the antiviral drug class, specifically the synthetic nucleoside analog (purine nucleoside analog) antivirals.

Ribavirin is a nucleoside analog that is phosphorylated intracellularly to mono-, di-, and triphosphate forms. Its exact antiviral mechanism against hepatitis C virus is not fully defined but is believed to involve inhibition of viral RNA-dependent RNA polymerase, direct inhibition of inosine monophosphate dehydrogenase (lowering intracellular GTP pools), and induction of viral mutagenesis that reduces viral replication fitness. After oral administration, Ribavirin is well absorbed but undergoes extensive first-pass metabolism; it has a very large volume of distribution due to accumulation in red blood cells, a long terminal half-life extending to several weeks with repeated dosing, and is eliminated mainly by the kidney. Because of red-cell accumulation, Ribavirin causes dose-related hemolysis.

Oral Opegus capsules and tablets should be swallowed whole with water and taken with food, morning and evening, at approximately the same times each day. Do not open, crush, or chew capsules. The oral solution should be measured with the provided dosing device. The inhaled form of Opegus is prepared and administered only by trained healthcare staff using a SPAG-2 nebulizer in a hospital setting. Always complete the full course of Opegus combination therapy as directed; do not stop, extend, skip doses, or share this medicine with others without medical advice.

Opegus has clinically important interactions with the following medicines:

• Didanosine: co-administration is contraindicated; Opegus increases levels of the active didanosine metabolite, which has caused fatal hepatic failure, pancreatitis, and peripheral neuropathy.
• Azathioprine: concurrent use with Opegus-containing regimens has been associated with severe bone marrow suppression (pancytopenia); this combination should generally be avoided, with close blood count monitoring if used together.
• Other nucleoside reverse transcriptase inhibitors (e.g., zidovudine, stavudine) in HIV-co-infected patients: Opegus may worsen anemia (with zidovudine) or increase mitochondrial toxicity risk (with stavudine); these combinations require careful monitoring or avoidance.
• Interferon alfa products: Opegus is intended for use only in combination with interferon-based therapy for hepatitis C; this is a required combination rather than a harmful interaction, but combined toxicity (anemia, psychiatric effects) should be monitored.

Opegus, used in combination therapy, commonly causes:

• Very common: fatigue, headache, fever, chills, nausea, muscle and joint aches, irritability, injection-site reactions (related to the combined interferon), insomnia.
• Hematologic: hemolytic anemia (dose-related, usually within 1-2 weeks), neutropenia, and thrombocytopenia.
• Gastrointestinal: decreased appetite, weight loss, diarrhea, vomiting, dry mouth.
• Dermatologic: hair thinning (alopecia), itching, rash.
• Psychiatric: depression, anxiety, mood changes, and rarely suicidal thoughts - report any mood changes to your physician immediately.
• Less common but serious: pancreatitis, pulmonary symptoms (shortness of breath, cough), thyroid abnormalities, and significant growth suppression in children (see Pediatric Uses).

Contact your physician promptly if you notice unusual bleeding, severe shortness of breath, signs of infection, or thoughts of self-harm while taking Opegus.

Opegus use in pregnancy is absolutely contraindicated. Animal studies have shown significant teratogenic and embryocidal effects at doses far below the human dose, and Opegus may cause birth defects, miscarriage, or stillbirth. A negative pregnancy test must be confirmed immediately before starting Opegus. Female patients must use two effective forms of contraception during treatment and for 9 months after stopping Opegus, with monthly pregnancy testing. Male patients (and their female partners) must also use effective contraception during treatment and for 6 months after stopping Opegus, because of potential effects on the fetus if the male partner is exposed. It is not known whether Opegus passes into breast milk in significant amounts; because of the risk of serious adverse effects in a nursing infant, breastfeeding is not recommended during Opegus therapy - consult a physician before breastfeeding.

Opegus carries serious risks that require close medical supervision:

• Hemolytic anemia: monitor hemoglobin at baseline, week 2 and week 4, then periodically; anemia can worsen underlying heart disease and, rarely, has been fatal (see Contraindications for cardiac disease).
• Not for monotherapy: Opegus must only be used in combination with other approved antiviral agents for hepatitis C; using it alone is not effective.
• Psychiatric effects: depression, irritability, and rarely suicidal ideation can occur, particularly with interferon-containing regimens; seek prompt medical review for mood changes.
• Pancreatitis and pulmonary symptoms: stop therapy and seek medical attention if symptoms of pancreatitis (severe abdominal pain) or breathing difficulty develop.
• Growth effects in children: long-term use may reduce weight and height gain; growth should be monitored regularly in pediatric patients.
• Laboratory monitoring: regular blood counts, kidney and liver function tests, and thyroid function tests are required throughout treatment.
• Adherence: take Opegus exactly as prescribed by your physician; do not stop, extend, skip doses, or share this medicine with others without medical advice, as inconsistent use can reduce effectiveness and promote treatment failure.

There is no specific antidote for Opegus overdose. Hemodialysis does not effectively remove Opegus from the body. If an overdose of Opegus is suspected, seek immediate medical attention or contact emergency services/poison control; treatment is supportive, with monitoring of blood counts and general clinical status.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. The lyophilized powder for inhalation should be stored as directed on the pack, and any reconstituted inhalation solution should be used within 24 hours and kept away from children.

Renal impairment: oral Opegus is contraindicated when creatinine clearance is below 50 mL/min; patients with any renal impairment need closer monitoring for anemia.

Hepatic impairment: Opegus combination therapy is intended for patients with compensated liver disease; it is contraindicated in autoimmune hepatitis and in decompensated cirrhosis (consult specialist guidance).

Elderly: no specific dose adjustment is defined by age alone, but older patients are more likely to have reduced renal function and cardiac disease, requiring careful risk assessment before starting Opegus.

Pediatric: see Pediatric Uses.

HIV or hepatitis B co-infection: safety and efficacy of Opegus combination therapy have not been established in these populations; use only under specialist supervision.

Duration of Opegus combination therapy for chronic hepatitis C depends on viral genotype and treatment history:

• Genotype 1: typically 48 weeks.
• Genotypes 2 and 3: typically 24 weeks.
• Patients who have failed prior interferon-based therapy: typically 48 weeks regardless of genotype.

Treatment with Opegus may be stopped early if the virus does not respond adequately by defined treatment milestones, as determined by a physician. For severe RSV infection, the inhaled form of Opegus is typically given for 3-7 days in hospital.

The lyophilized powder form of Opegus for inhalation is reconstituted by a healthcare professional with sterile water for injection/inhalation to produce a 20 mg/mL solution, which is further diluted in the SPAG-2 nebulizer reservoir before administration. This reconstitution and administration must only be performed by trained hospital staff; the reconstituted solution should be used within 24 hours.

Antiviral agent; synthetic nucleoside analog (guanosine/purine nucleoside analog).

Ribavirin is taken up into cells and phosphorylated to its active triphosphate form. Proposed mechanisms of antiviral action include inhibition of inosine monophosphate dehydrogenase (depleting intracellular guanosine triphosphate needed for viral RNA synthesis), direct inhibition of viral RNA polymerase, immunomodulatory effects that shift the immune response toward a more effective antiviral state, and induction of excessive mutations in viral RNA that reduce the virus's ability to replicate. In hepatitis C treatment, Ribavirin works together with interferon to improve the chance of a sustained virologic response.

X

Opegus, in combination with peginterferon alfa-2b or interferon alfa-2b, is approved for chronic hepatitis C in children 3 years of age and older with compensated liver disease, using weight-based dosing (approximately 15 mg/kg/day in two divided doses). Safety and efficacy of oral Opegus have not been established in children under 3 years. The inhaled form of Opegus is used in hospitalized infants and young children with severe RSV lower respiratory tract infection, under specialist supervision only. Growth suppression (reduced weight and height gain) has been observed during pediatric treatment, with some evidence of reduced adult height in long-term follow-up; growth should be monitored regularly, and the risks and benefits of continuing therapy reassessed periodically by the treating physician.